{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-076521","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.093618+00:00","generated_at":"2026-05-15T23:31:20.780624+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biodesix Q4 revenue $28.8M (+41% YoY), first-ever positive Adj EBITDA $0.5M","bullets":["Q4 total revenue $28.8M (+41% YoY), gross margin 83% (up 400bps), net loss improved 52% to $4.0M.","Diagnostic test revenue $25.1M (+46% YoY), volumes 18,000 tests (+23%), average rev per test increased.","FY2025 total revenue $88.5M, above raised guidance of $84-86M; FY2026 guidance $106-112M (+23% mid-point).","First-ever positive Adj EBITDA of $0.5M in Q4; FY2025 Adj EBITDA loss $17.5M improved 21% YoY.","Post-quarter: amended Perceptive term loan to Nov 2028, raised $14.7M via ATM; pro forma cash $33.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-076521","json":"https://secwatch.observer/filing/0001193125-26-076521.json","markdown":"https://secwatch.observer/filing/0001193125-26-076521.md","text":"https://secwatch.observer/filing/0001193125-26-076521.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000119312526076521/0001193125-26-076521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000119312526076521/bdsx-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:31:20.780624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}